Want to see ARCT full AI Analyst Report?
ARCT Stock Chart & Stats
$8.85
-$1.70(-8.19%)
At close: 4:00 PM EST
$8.85
-$1.70(-8.19%)
Day’s Range― - ―
52-Week Range$5.50 - $24.17
Previous CloseN/A
Volume109.32K
Average Volume (3M)1.12M
Market Cap
$475.80M
Enterprise Value$22.45
Total Cash (Recent Filing)$191.48M
Total Debt (Recent Filing)$22.93M
Price to Earnings (P/E)―
Beta2.33
Next Earnings
Nov 11, 2026EPS Estimate
-0.68Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.33
Shares Outstanding28,423,069
10 Day Avg. Volume2,301,164
30 Day Avg. Volume1,117,599
Financial Highlights & Ratios
PEG Ratio0.13
Price to Book (P/B)0.78
Price to Sales (P/S)2.50
P/FCF Ratio-2.26
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$24.00Price Target Upside171.19% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
EPS Forecast (FY)-3.45
Revenue Forecast (FY)$18.64M
Bulls Say, Bears Say
Bulls Say
ARCT-810 Clinical ProgressCompletion of Phase II enrollment and dosing reduces execution risk for this rare-disease program. Upcoming data and regulatory planning could support a late-stage path, strengthen clinical validation, and create partnering or commercialization opportunities.
Thermo Fisher Development SupportA strategic manufacturing and research framework gives ARCT-032 access to scaled development capabilities if it advances to Phase III. This can reduce infrastructure requirements, improve execution readiness, and support a potential commercial launch.
Validated Sa-mRNA PlatformRegaining global rights restores control over a validated sa-mRNA platform and an asset with existing international approvals. Lower-dose manufacturing and an established regulatory footprint may improve future partnering, licensing, or commercialization flexibility.
Bears Say
Severe Revenue ContractionThe collapse in collaboration revenue exposes the company’s dependence on milestone timing and partnered programs rather than recurring product sales. Sustained monetization will require successful vaccine partnering, commercialization, or new collaborations.
Persistent Cash BurnOngoing operating and free-cash-flow losses consume resources while clinical programs remain costly and uncommercialized. Although management cites a runway beyond 2028, continued burn could reduce flexibility and increase dependence on future funding or partnerships.
Clinical And Regulatory UncertaintyThe pipeline’s value depends on efficacy, safety, and regulatory outcomes that remain unproven. Delays or unfavorable results could postpone commercialization, weaken partnering leverage, and leave the company carrying development costs without product revenue.
Arcturus Therapeutics News
ARCT FAQ
What was Arcturus Therapeutics’s price range in the past 12 months?
Arcturus Therapeutics lowest stock price was $5.50 and its highest was $24.17 in the past 12 months.
What is Arcturus Therapeutics’s market cap?
Arcturus Therapeutics’s market cap is $475.80M.
When is Arcturus Therapeutics’s upcoming earnings report date?
Arcturus Therapeutics’s upcoming earnings report date is Nov 11, 2026 which is in 68 days.
How were Arcturus Therapeutics’s earnings last quarter?
Arcturus Therapeutics released its earnings results on Aug 06, 2026. The company reported -$0.84 earnings per share for the quarter, beating the consensus estimate of -$0.996 by $0.156.
Is Arcturus Therapeutics overvalued?
According to Wall Street analysts Arcturus Therapeutics’s price is currently Undervalued.
Does Arcturus Therapeutics pay dividends?
Arcturus Therapeutics pays a Notavailable dividend of $0.06 which represents an annual dividend yield of N/A. See more information on Arcturus Therapeutics dividends here
What is Arcturus Therapeutics’s EPS estimate?
Arcturus Therapeutics’s EPS estimate is -0.68.
How many shares outstanding does Arcturus Therapeutics have?
Arcturus Therapeutics has 28,423,069 shares outstanding.
What happened to Arcturus Therapeutics’s price movement after its last earnings report?
Arcturus Therapeutics reported an EPS of -$0.84 in its last earnings report, beating expectations of -$0.996. Following the earnings report the stock price went up 21.875%.
Which hedge fund is a major shareholder of Arcturus Therapeutics?
Currently, no hedge funds are holding shares in ARCT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Arcturus Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$24.00 (171.19% Upside)
$24.00 (171.19% Upside)
Blogger Sentiment
Bullish
ARCT Sentiment 67%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 132.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▲ 0.7%
Last 30 Days ▼ 4.9%
Last 30 Days ▼ 4.9%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
0.23%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-27.47%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Arcturus Therapeutics
Arcturus Therapeutics Holdings Inc. is a biotechnology company focused on RNA-based medicines, developing a pipeline of vaccines for infectious diseases alongside treatments for rare liver and respiratory conditions across the United States. Its notable development programs encompass LUNAR-OTC, designed for ornithine transcarbamylase (OTC) deficiency, and LUNAR-CF, targeting cystic fibrosis lung disease caused by specific CFTR gene mutations. The company also advances vaccine initiatives such as LUNAR-COV19 and LUNAR-FLU. Arcturus has cultivated a range of strategic collaborations, including partnerships with Vinbiocare Biotechnology Joint Stock Company for manufacturing COVID-19 vaccines; Janssen Pharmaceuticals, Inc., to create nucleic acid-based therapies for hepatitis B virus; Ultragenyx Pharmaceutical, Inc., for developing mRNA therapeutics aimed at rare disease targets; CureVac AG, to progress mRNA therapeutic and vaccine candidates across various indications; the Singapore Economic Development Board and Duke-NUS Medical School, specifically for the LUNAR-COV19 vaccine; and Millennium Pharmaceuticals, Inc., focused on discovering siRNA medicines for non-alcoholic steatohepatitis (NASH). Founded in 2013, Arcturus Therapeutics maintains its corporate headquarters in San Diego, California.
ARCT Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presents a balanced mix of strategic, clinical, and financial developments. Positive operational milestones include completed enrollment for ARCT-810, continued ARCT-032 Phase II progress with international expansion, regained global rights to a validated sa-mRNA vaccine platform (KOSTAIVE) along with a $12M settlement, a Thermo Fisher manufacturing collaboration for CF, and a completed Phase I pandemic flu study with BARDA support and an accepted manuscript. Offsetting these positives are material near-term financial headwinds: revenue declined sharply year-over-year (~-89% quarter, ~-91% six months) as the CSL collaboration wound down, cash declined by ~17% in H1 2026, and Arcturus now bears the responsibility to commercialize or partner its vaccine portfolio. R&D spending decreased materially (~-40%) and G&A saw modest increases due to legal fees. Overall, strategic and clinical advances are meaningful but are balanced by significant revenue and cash impacts that require successful commercialization/partnering and upcoming data readouts to validate the company’s runway and prospects.View all ARCT earnings summariesARCT Stock 12 Month Forecast
Average Price Target
$24.00
▲(171.19% Upside)
Technical Analysis
Rigel
―
Arvinas Holding Company
―
Compass Therapeutics
―
Olema Pharmaceuticals
―
Erasca
―
Ownership Overview
7.26%
Insiders
23.74% Mutual Funds
31.09% Other Institutional Investors
15.47% Public Companies and
Individual Investors